KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Free Cash Flow (2016 - 2025)

Globus Medical (GMED) has disclosed Free Cash Flow for 15 consecutive years, with $353.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 18.12% year-over-year to $353.6 million, compared with a TTM value of $740.0 million through Dec 2025, up 44.71%, and an annual FY2025 reading of $740.0 million, up 44.71% over the prior year.
  • Free Cash Flow was $353.6 million for Q4 2025 at Globus Medical, up from $144.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $353.6 million in Q4 2025 and bottomed at -$4.7 million in Q4 2022.
  • Average Free Cash Flow over 5 years is $90.6 million, with a median of $49.9 million recorded in 2021.
  • The sharpest move saw Free Cash Flow crashed 120.71% in 2022, then surged 2288.65% in 2023.
  • Year by year, Free Cash Flow stood at $22.8 million in 2021, then tumbled by 120.71% to -$4.7 million in 2022, then soared by 2288.65% to $103.5 million in 2023, then soared by 189.13% to $299.4 million in 2024, then grew by 18.12% to $353.6 million in 2025.
  • Business Quant data shows Free Cash Flow for GMED at $353.6 million in Q4 2025, $144.7 million in Q3 2025, and $74.4 million in Q2 2025.